Landos Biopharma Inc (LABP)
22.44
-0.01
(-0.04%)
USD |
NASDAQ |
May 15, 16:00
22.44
0.00 (0.00%)
After-Hours: 16:06
Landos Biopharma Cash from Financing (Quarterly): 0.00 for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 0.00 |
| December 31, 2023 | 0.00 |
| September 30, 2023 | 0.00 |
| June 30, 2023 | -0.099M |
| March 31, 2023 | 13.67M |
| December 31, 2022 | 0.00 |
| September 30, 2022 | 0.00 |
| June 30, 2022 | 0.00 |
| March 31, 2022 | 0.00 |
| Date | Value |
|---|---|
| December 31, 2021 | 0.624M |
| September 30, 2021 | 0.219M |
| June 30, 2021 | 0.00 |
| March 31, 2021 | 90.76M |
| December 31, 2020 | 1.518M |
| September 30, 2020 | 0.00 |
| June 30, 2020 | 0.00 |
| March 31, 2020 | 0.00 |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.099M
Minimum
Jun 2023
90.76M
Maximum
Mar 2021
6.276M
Average
--
Median
Mar 2020
Cash from Financing (Quarterly) Benchmarks
| AbbVie Inc | 10.82B |
| Fusion Pharmaceuticals Inc | 64.01M |
| Masimo Corp | -26.50M |
| Kinnate Biopharma Inc (DELISTED) | 0.00 |
| Invivyd Inc | 39.10M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -8.498M |
| Free Cash Flow | -20.80M |
| Free Cash Flow Per Share (Quarterly) | -1.369 |
| Free Cash Flow Yield | -14.94% |